Envirotainer, the specialist in temperature-sensitive pharmaceutical shipments, has been awarded the “Most Diverse Range of Packaging” award at Cold Chain Unbroken 2024. This recognition highlights the company’s commitment to delivering reliable packaging solutions for all stages of the pharmaceutical lifecycle and across all industry segments.
The award reflects the growing need for more versatile and effective cold chain solutions as the demand for transporting high-value, temperature-sensitive medications continues to rise. Having integrated va-Q-tec’s advanced passive cooling solutions into its own active solution portfolio, Envirotainer now enables pharmaceutical companies to transport products at any temperature and stage of the product lifecycle, whether for clinical trials, active pharmaceutical ingredients (APIs), or finished medicines for commercial use.
From small-scale shipments to larger commercial quantities, Envirotainer’s solutions are designed to maintain precise temperatures over extended periods. This endurance helps sensitive pharmaceuticals, including precision medicines, advanced cell and gene therapies, vaccines, and treatments for chronic diseases, safely reach patients in remote and challenging locations.
“This recognition reflects our dedication to providing solutions that help all patients, no matter where they are, gain access to life-saving medicines and therapies,” said Jonathon Haydn-Evans, Head of Sales, APAC. “Pharmaceutical companies face tougher challenges than ever, with the growing demand for diverse medications and the need to reach patients in remote regions. We support them by providing precise, temperature-controlled solutions that keep vital medicines safe, even in difficult conditions.”
Envirotainer’s extensive global network, combined with the largest fleet in the industry, enables pharmaceutical companies to overcome complex logistical challenges. With solutions readily available when needed, this allows faster access to temperature-controlled packaging, helping deliver critical treatments to patients without delays.
